These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 9032579)

  • 41. Role of cyclooxygenase-1 and -2 in health and disease.
    Lipsky PE
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):8-12. PubMed ID: 10193997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.
    Hawkey C; Talley NJ; Yeomans ND; Jones R; Sung JJ; Långström G; Naesdal J; Scheiman JM;
    Am J Gastroenterol; 2005 May; 100(5):1028-36. PubMed ID: 15842575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of NSAIDs on prostaglandin synthesis].
    Watanabe T; Higuchi K; Tominaga K; Uchida T; Fujiwara Y; Arakawa T
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():190-4. PubMed ID: 11979776
    [No Abstract]   [Full Text] [Related]  

  • 47. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
    Wright JM; Perry TL; Bassett KL; Chambers GK
    JAMA; 2001 Nov; 286(19):2398-400. PubMed ID: 11712925
    [No Abstract]   [Full Text] [Related]  

  • 48. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
    Hrachovec JB; Mora M
    JAMA; 2001 Nov; 286(19):2398; author reply 2399-400. PubMed ID: 11712924
    [No Abstract]   [Full Text] [Related]  

  • 49. Selective inhibitors of COX-2--are they safe for the stomach?
    Giercksky KE; Haglund U; Rask-Madsen J
    Scand J Gastroenterol; 2000 Nov; 35(11):1121-4. PubMed ID: 11145280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [NSAIDs for therapy of rheumatoid arthritis. Introduction].
    Takasaki Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():473-6. PubMed ID: 15799402
    [No Abstract]   [Full Text] [Related]  

  • 51. [The choice of selective COX-2 inhibitors].
    Hiratsuka T; Sakamoto C
    Nihon Rinsho; 2007 Oct; 65(10):1819-23. PubMed ID: 17926530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic tools to tailor cancer prevention by NSAIDs.
    Ulrich CM; Bigler J; Potter JD
    Discov Med; 2006 Apr; 6(32):71-4. PubMed ID: 17234129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
    Lanas A
    N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12802035
    [No Abstract]   [Full Text] [Related]  

  • 55. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
    Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
    Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
    Stover RR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134855
    [No Abstract]   [Full Text] [Related]  

  • 58. COX-1-sparing NSAIDs--is the enthusiasm justified?
    Peterson WL; Cryer B
    JAMA; 1999 Nov; 282(20):1961-3. PubMed ID: 10580464
    [No Abstract]   [Full Text] [Related]  

  • 59. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
    Geis GS
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
    [No Abstract]   [Full Text] [Related]  

  • 60. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage.
    Takeuchi K; Tanaka A; Kato S; Amagase K; Satoh H
    Clin Chim Acta; 2010 Apr; 411(7-8):459-66. PubMed ID: 20074562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.